KZIA

3.02

3.78% 0.11

Dopo l'orario di chiusura: 3.03 0.010 +0.33%

Kazia Therapeutics Limited Adr (KZIA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.91

Aprire:

$2.95

Volume 24 ore:

42,463

Relative Volume:

0.36

Capitalizzazione di mercato:

$13.15M

Reddito:

Utile/perdita netta:

$-13.52M

Rapporto P/E:

-4.0811

EPS:

-0.74

Flusso di cassa netto:

$-10.03M

1 W Prestazione:

-0.33%

1M Prestazione:

-45.86%

6M Prestazione:

+44.71%

1 anno Prestazione:

-29.77%

Intervallo 1D:

$2.85

$3.20

Intervallo di 1 settimana:

$2.85

$3.20

Portata 52W:

$1.866

$15.80

Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile

Nome

Kazia Therapeutics Limited Adr

Settore

Healthcare (1173)

Industria

Biotechnology (668)

Telefono

01161298780088

Indirizzo

140 WICKS RD, NEW SOUTH WALES 2113, NSW

Dipendente

Cinguettio

@KaziaTx

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

KZIA's Discussions on Twitter

Confronta KZIA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KZIA Kazia Therapeutics Limited Adr	3.02	13.15M	0	-13.52M	-10.03M	-0.74
VRTX Vertex Pharmaceuticals Inc	410.65	105.75B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.68	78.76B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	632.04	37.79B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.50	31.28B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.77	27.28B	3.30B	-501.07M	1.03B	-2.1146

Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-10-14	Iniziato	Maxim Group	Buy
2021-01-05	Iniziato	H.C. Wainwright	Buy

Kazia Therapeutics Limited Adr Borsa (KZIA) Ultime notizie

Dec 11, 2024

SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow

Dec 11, 2024

Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan

Dec 11, 2024

Nov 04, 2024

Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India

Nov 04, 2024

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan

Nov 04, 2024

Oct 30, 2024

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 30, 2024

Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 29, 2024

Oct 28, 2024

Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq

Oct 28, 2024

Oct 16, 2024

Ratios in Focus: Analyzing Kazia Therapeutics Limited ADR (KZIA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 16, 2024

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance

Oct 16, 2024

Kazia Therapeutics Stock Scheduled to Reverse Split on Monday, October 28th (NASDAQ:KZIA) - Defense World

Oct 16, 2024

Oct 11, 2024

B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga

Oct 11, 2024

Oct 02, 2024

Paxalisib shows promise in brain metastasis treatment - Investing.com

Oct 02, 2024

It makes sense and dollars to buy Kazia Therapeutics Limited ADR (KZIA) stock - SETE News

Oct 02, 2024

Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex

Oct 02, 2024

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan

Oct 02, 2024

Oct 01, 2024